方盛制药：控股子公司紫英颗粒药物临床试验获批

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced that its subsidiary, Guangdong Fangsheng Rongo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its innovative traditional Chinese medicine, Ziying Granules, which is based on years of clinical experience in treating pelvic inflammatory disease [1] Company Summary - Fangsheng Pharmaceutical's subsidiary has developed Ziying Granules, which is aimed at treating pelvic inflammatory disease [1] - The approval for clinical trials marks a significant milestone in the company's drug development efforts [1]